Compare COOK & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | TARA |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | United States |
| Employees | 433 | N/A |
| Industry | Wholesale Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.4M | 159.6M |
| IPO Year | 2021 | 2014 |
| Metric | COOK | TARA |
|---|---|---|
| Price | $51.74 | $2.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $62.33 | $25.71 |
| AVG Volume (30 Days) | 21.2K | ★ 1.3M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $559,520,000.00 | $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $2.51 |
| 52 Week High | $86.59 | $7.82 |
| Indicator | COOK | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 28.82 |
| Support Level | $47.08 | N/A |
| Resistance Level | $52.05 | $4.13 |
| Average True Range (ATR) | 2.86 | 0.21 |
| MACD | 0.80 | -0.05 |
| Stochastic Oscillator | 70.20 | 16.71 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.